MB 66

Drug Profile

MB 66

Alternative Names: HIV/HSV microbicide - Mapp; Mapp 66; MB66

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mapp Biopharmaceutical
  • Developer Boston University; Integrated Preclinical/Clinical Program for HIV Topical Microbicides Consortium; Mapp Biopharmaceutical; The Miriam Hospital
  • Class Monoclonal antibodies
  • Mechanism of Action HIV envelope protein gp120 inhibitors; HIV envelope protein gp41 inhibitors; HIV fusion inhibitors; Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HIV infections
  • No development reported Herpes simplex virus infections

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for phase-I development in Herpes-simplex-virus-infections in USA (Vaginal, Film)
  • 01 Jan 2016 Phase-I clinical trials in HIV infections in USA (Vaginal) (NCT02579083)
  • 09 Oct 2015 LeafBio plans the phase I VAST trial for HIV infections and Herpes simplex virus infections in USA (NCT02579083)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top